VVOS vs. RCEL, OBIO, ZJYL, EDAP, NSPR, SPAI, FONR, HYPR, BDMD, and APYX
Should you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Avita Medical (RCEL), Orchestra BioMed (OBIO), Jin Medical International (ZJYL), Edap Tms (EDAP), InspireMD (NSPR), Safe Pro Group (SPAI), Fonar (FONR), Hyperfine (HYPR), Baird Medical Investment (BDMD), and Apyx Medical (APYX). These companies are all part of the "medical equipment" industry.
Vivos Therapeutics vs. Its Competitors
Vivos Therapeutics (NASDAQ:VVOS) and Avita Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
In the previous week, Avita Medical had 7 more articles in the media than Vivos Therapeutics. MarketBeat recorded 8 mentions for Avita Medical and 1 mentions for Vivos Therapeutics. Avita Medical's average media sentiment score of 0.78 beat Vivos Therapeutics' score of 0.00 indicating that Avita Medical is being referred to more favorably in the news media.
Vivos Therapeutics presently has a consensus target price of $4.82, indicating a potential upside of 9.47%. Avita Medical has a consensus target price of $12.40, indicating a potential upside of 189.04%. Given Avita Medical's higher possible upside, analysts plainly believe Avita Medical is more favorable than Vivos Therapeutics.
Avita Medical has a net margin of -68.87% compared to Vivos Therapeutics' net margin of -99.49%. Vivos Therapeutics' return on equity of -232.76% beat Avita Medical's return on equity.
26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 3.0% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Avita Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Vivos Therapeutics has higher earnings, but lower revenue than Avita Medical. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks.
Vivos Therapeutics has a beta of 7.02, indicating that its share price is 602% more volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.
Summary
Avita Medical beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Vivos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vivos Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VVOS) was last updated on 9/5/2025 by MarketBeat.com Staff
Free VVOS Stock Alerts